ES2074441T3 - Compuestos espiro heterociclicos y su preparacion. - Google Patents

Compuestos espiro heterociclicos y su preparacion.

Info

Publication number
ES2074441T3
ES2074441T3 ES88309095T ES88309095T ES2074441T3 ES 2074441 T3 ES2074441 T3 ES 2074441T3 ES 88309095 T ES88309095 T ES 88309095T ES 88309095 T ES88309095 T ES 88309095T ES 2074441 T3 ES2074441 T3 ES 2074441T3
Authority
ES
Spain
Prior art keywords
group
formula
atom
alkyl
chem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88309095T
Other languages
English (en)
Inventor
Shin-Ichi Tsukamoto
Hitoshi Nagaoka
Shinji Usuda
Masatomi Harada
Toshinari Tamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2074441T3 publication Critical patent/ES2074441T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Abstract

COMPUESTOS ESPIRO - HETEROCICLICOS REPRESENTADOS POR LA FORMULA(I), Y SUS SALES. ESTOS COMPUESTOS ACTUAN SOBRE LOS RECEPTORES MUSCARINICOS DE ACETILCOLINA, ACTIVANDO LAS FUNCIONES NERVIOSAS DE LA ACETILCOLINA EN EL SISTEMA NERVIOSO CENTRAL.
ES88309095T 1987-10-05 1988-09-30 Compuestos espiro heterociclicos y su preparacion. Expired - Lifetime ES2074441T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP25210487 1987-10-05
JP28629787 1987-11-12
JP8432788 1988-04-05

Publications (1)

Publication Number Publication Date
ES2074441T3 true ES2074441T3 (es) 1995-09-16

Family

ID=27304516

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88309095T Expired - Lifetime ES2074441T3 (es) 1987-10-05 1988-09-30 Compuestos espiro heterociclicos y su preparacion.

Country Status (14)

Country Link
US (4) US4940795A (es)
EP (1) EP0311313B1 (es)
JP (1) JPH0236183A (es)
KR (1) KR970007947B1 (es)
CN (1) CN1036653C (es)
AT (1) ATE122353T1 (es)
AU (1) AU621559B2 (es)
CA (1) CA1337817C (es)
DE (1) DE3853758T2 (es)
DK (1) DK554288A (es)
ES (1) ES2074441T3 (es)
GR (1) GR3016995T3 (es)
HU (1) HU211687A9 (es)
NO (1) NO171109C (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853758T2 (de) * 1987-10-05 1995-09-07 Yamanouchi Pharma Co Ltd Heterozyklische Spiroverbindungen und ihre Herstellung.
US5412096A (en) * 1987-10-05 1995-05-02 Yamanouchi Pharmaceutical Co., Ltd. Hydrochloride salts of heterocyclic spiro compounds
US5594000A (en) * 1989-06-21 1997-01-14 Astra Ab Spirofurane derivatives
US5075317A (en) * 1989-06-21 1991-12-24 Fisons Corporation Spirofurane derivatives
US5407938A (en) * 1990-04-10 1995-04-18 Israel Institute For Biological Research Certain 1-methyl-piperidine-4-spiro-4'-(1'-3'-oxazolines) and corresponding -(1',3' thiazolines)
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US5852029A (en) * 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
US5073560A (en) * 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
IE914238A1 (en) * 1990-12-19 1992-07-01 Fisons Corp Novel spirofurane derivatives
ES2118814T3 (es) * 1991-05-15 1998-10-01 Yamanouchi Pharma Co Ltd L-tartrato de (-)-(s)-2,8-dimetil-3-metilen-1-oxa-8-azaspiro(4,5)decano.
ATE169001T1 (de) * 1993-01-28 1998-08-15 Merck & Co Inc Substituierte spiro-azaringen als tachykinine rezeptor antagonisten
US5688806A (en) * 1993-03-04 1997-11-18 Pfizer Inc. Spiroazacyclic derivatives as substance P antagonists
JP2983141B2 (ja) * 1993-10-06 1999-11-29 株式会社三和化学研究所 新規化合物及び該化合物を有効成分とする脳機能改善剤
JP2002500652A (ja) 1997-05-30 2002-01-08 ニューロサーアチ・アクティーゼルスカブ スピロ−キヌクリジン誘導体、その製造方法及びその使用方法
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
BR0013085A (pt) * 1999-08-13 2002-04-23 Aventis Cropscience Gmbh Compostos espiro heterocìclicos como pesticidas
EP1328261A2 (en) * 2000-04-12 2003-07-23 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
JP2003063964A (ja) * 2001-08-28 2003-03-05 Senju Pharmaceut Co Ltd ドライアイまたはドライアイを伴なう疾病の予防治療剤
JP5254616B2 (ja) 2004-09-13 2013-08-07 クロノ セラピューティクス、インコーポレイテッド 生物学的同調性（ｂｉｏｓｙｎｃｈｒｏｎｏｕｓ）経皮的薬物送達
CN101232882A (zh) * 2005-07-26 2008-07-30 千寿制药株式会社 经皮吸收性眼用制剂
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
AU2007223036A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (en) * 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
ITMI20061279A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Agonisti nicotinici selettivi per il sottotipo recettoriale alfa7,procedimento per la loro preparazione e relative composizioni farmaceutiche
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008036846A2 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
EP2322166A1 (en) 2007-04-02 2011-05-18 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
RU2506266C2 (ru) * 2009-01-26 2014-02-10 Израэл Инститьют Фо Байолоджикал Рисерч Бициклические гетероциклические спиросоединения
US9034891B2 (en) 2009-01-26 2015-05-19 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2716049T3 (es) 2012-07-13 2019-06-07 Pain Therapeutics Inc Un método para inhibir la fosforilación de tau
US9433604B2 (en) 2013-10-08 2016-09-06 Pain Therapeutics Inc. Method for inhibiting growth of cancer cells
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
AU2018205529B2 (en) 2017-01-06 2023-08-10 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
JP7420797B2 (ja) 2018-05-29 2024-01-23 モーニングサイド ベンチャー インベストメンツ リミテッド 薬剤送達の方法及びシステム
CN115124545B (zh) * 2022-08-31 2023-01-03 南京远淑医药科技有限公司 一种***释放激素受体拮抗剂中间体的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3305556A (en) * 1962-11-23 1967-02-21 Pfizer & Co C Novel hypoglycemic agents
NL124853C (es) * 1963-07-19
SU335944A1 (ru) * 1970-12-15 1976-01-25 Научно-исследовательский институт химии Саратовского государственного университета им.Н.Г.Чернышевского Способ получени соединений р да 1-окса6-азаспиро(4,4)нонана
GB1301254A (es) * 1971-07-08 1972-12-29
US3784551A (en) * 1971-07-08 1974-01-08 Yoshitomi Pharmaceutical 2-oxo-1,4-dioxa-8-azaspiro (4.5) decanes and related compounds
US3839273A (en) * 1971-11-13 1974-10-01 Sankyo Co N-substituted piperidine derivatives, process for preparing the same and their use as stabilizers
SU434735A1 (ru) * 1972-03-01 1975-12-15 Научно-исследовательский институт химии Саратовского государственного университета им.Н.Г.Чернышевского Способ получени 7-метил-(или 2,7диметил)-2-метокси- -пропионитрил1-окса-6-азаспиро-(4,4)-нонана
SU465399A1 (ru) * 1973-07-19 1975-03-30 Научно-исследовательский институт химии при Саратовском государственном университете им.Н.Г.Чернышевского Способ получени натриевых солей 2-метокси- -карбоксиэтил-1-окса6-азаспиро-(4,4)-нонана
IL48452A (en) * 1975-11-11 1979-07-25 Purdue Frederick Co Spiro (1,3-dioxolane-4,3') quinuclidines,their preparationand pharmaceutical compositions comprising them
US4321379A (en) * 1981-01-28 1982-03-23 American Cyanamid Company 4-Aryl-1-oxa-8-azaspiro[4,5]dec-3-en-2-ones
SU1002294A1 (ru) * 1981-08-14 1983-03-07 Ордена Трудового Красного Знамени Институт Тонкой Органической Химии Им.А.Л.Мнджояна 2,2-Диалкил-3-тиа-8-азаспиро/5,5/ундеканы
EP0189370A3 (de) * 1985-01-16 1988-01-27 Sandoz Ag Spiro-dioxolane, -dithiolane und -oxothiolane
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
US4981858A (en) * 1987-08-13 1991-01-01 State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research Optical isomers
DE3853758T2 (de) * 1987-10-05 1995-09-07 Yamanouchi Pharma Co Ltd Heterozyklische Spiroverbindungen und ihre Herstellung.
US5073560A (en) * 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents

Also Published As

Publication number Publication date
US4996210A (en) 1991-02-26
NO171109C (no) 1993-01-27
EP0311313A2 (en) 1989-04-12
DK554288A (da) 1989-05-26
AU621559B2 (en) 1992-03-19
EP0311313A3 (en) 1990-12-05
EP0311313B1 (en) 1995-05-10
CA1337817C (en) 1995-12-26
NO884406D0 (no) 1988-10-04
DK554288D0 (da) 1988-10-04
KR890006649A (ko) 1989-06-15
DE3853758T2 (de) 1995-09-07
HU211687A9 (en) 1995-12-28
CN1033629A (zh) 1989-07-05
JPH0544948B2 (es) 1993-07-07
DE3853758D1 (de) 1995-06-14
US5041549A (en) 1991-08-20
ATE122353T1 (de) 1995-05-15
KR970007947B1 (ko) 1997-05-19
NO171109B (no) 1992-10-19
JPH0236183A (ja) 1990-02-06
CN1036653C (zh) 1997-12-10
US4940795A (en) 1990-07-10
NO884406L (no) 1989-04-06
USRE34653E (en) 1994-07-05
GR3016995T3 (en) 1995-11-30
AU2344988A (en) 1989-04-06

Similar Documents

Publication Publication Date Title
ES2074441T3 (es) Compuestos espiro heterociclicos y su preparacion.
ATE79380T1 (de) 2-substituierte-e-kondensierte(1,2,4>triazolo(1,5-c>pyrimidine, pharmazeutische zubereitungen und ihre verwendung.
GR3005072T3 (es)
GR3020848T3 (en) 1,8-Naphthyridin-2-one derivatives
ES2063452T3 (es) Preparacion y uso de esteres y derivados de n-yodopropargil oxicarbonil aminoacido como agentes antimicrobianos.
AR241422A1 (es) Procedimiento para la preparacion de derivados de difenil(metil-etil-0 etenil) piperidinas.
DE69129165D1 (de) Prozess zur Darstellung von Lactamderivaten
MX170732B (es) Composicion de derivados de succinimida y su uso
ES2072095T3 (es) Derivados de tiazolidinona y oxazolidinona, su preparacion y su uso como vasodilatadores.
DE69411616T2 (de) Triazolopyridazin-Derivate, ihre Herstellung und Verwendung
ES8706690A1 (es) Un procedimiento para la preparacion de nuevos derivados de penem.
ATE38675T1 (de) Phosphatesterderivate und ihre verwendung als anti-krebsmittel.
NO891609D0 (no) Anti-hypertensive sulfonanilider.
AU546679B2 (en) Hydrogenated 1,4 thiazepine (thiazine) dione derivatives
DE3770117D1 (de) Neue 1-/ 3-(2-dialkylaminoaethoxy)-2-thienyl/-3-phenyl-1-propanone und ihre saeureadditionssalze und verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen.
FI903511A0 (fi) Pyrrolo (2,1-b) tiazolderivat.
KR860004040A (ko) 3,4-디아졸 유도체의 제조방법
DE3572815D1 (de) 1,3-dithiole derivatives
HUP9801716A1 (hu) 5H,10H-Imidazo[1,2-a]indeno[1,2-e]pirazin-4-on-származékok, eljárás előállításukra,az ezeket tartalmazó gyógyszerkészítmények és a vegyületek intermedierjei
IL86665A0 (en) Mitomycin analogs

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 311313

Country of ref document: ES